

**Listing of Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A method of inhibiting growth of ~~an~~ a recurrent autologous tumor in a mammal, comprising administering to said mammal after therapeutic intervention for a primary tumor a composition comprising taurolidine or a biologically active derivative thereof, in an amount sufficient to induce tumor cell death by apoptosis.
2. (Currently Amended) The method of claim 1, wherein said recurrent tumor is a tumor of the central nervous system.
3. (Currently Amended) The method of claim 1, wherein said recurrent tumor is a ~~neuroblastoma~~ glioblastoma.
4. (Currently Amended) The method of claim 1, wherein said tumor is ~~an astrocytoma~~ ovarian cancer.
5. (Currently Amended) The method of claim 1, wherein said ~~tumor is carcinomatous~~ meningitis composition is administered to directly contact the surface of a cell of said recurrent tumor.
6. (Currently Amended) The method of ~~claim 1~~ claim 4, wherein said ~~tumor is a CNS lymphoma~~ composition is administered by intraperitoneal lavage.
7. (Currently Amended) The method of ~~claim 1~~ claim 3, wherein said ~~tumor is a glioma~~ composition is administered systematically.
8. (Currently Amended) The method of ~~claim 1~~ claim 7, wherein said composition is administered ~~at a dose sufficient to induce tumor cell death by apoptosis~~ intravenously.
9. (Cancelled)
10. (Original) The method of claim 1, wherein said composition comprises taurolidine.

11. (Original) The method of claim 1, wherein said composition comprises a taurolidine derivative or metabolite.
12. (Original) The method of claim 1, further comprising administering a chemotherapeutic agent selected from the group consisting of an antimetabolite, a purine or pyrimidine analogue, an alkylating agent, an intercalating agent, a crosslinking agent, and an antibiotic.
13. (Currently Amended) A method of inhibiting growth of ~~an~~ a recurrent autologous tumor in a mammal, comprising administering to said mammal after therapeutic intervention for a primary tumor a composition comprising taurultam or a biologically active derivative thereof, in an amount sufficient to induce tumor cell death by apoptosis.
14. (Currently Amended) The method of claim 13, wherein said recurrent tumor is a tumor of the central nervous system.
15. (Currently Amended) The method of claim 13, wherein said tumor is a ~~neuroblastoma~~ glioblastoma.
16. (Currently Amended) The method of claim 13, wherein said tumor is ~~an astrocytoma~~ ovarian cancer.
17. (Current Amended) The method of claim 13, wherein said ~~tumor is carcinomatous meningitis~~ composition is administered to directly contact the surface of a cell of said recurrent tumor.
18. (Currently Amended) The method of ~~claim 13~~ claim 16, wherein said ~~tumor is a CNS lymphoma~~ composition is administered by intraperitoneal lavage.
19. (Currently Amended) The method of ~~claim 13~~ claim 15, wherein said ~~tumor is a glioma~~ composition is administered systematically.
20. (Currently Amended) The method of ~~claim 13~~ claim 19, wherein said composition is administered ~~at a dose sufficient to induce tumor cell death by apoptosis~~ intravenously.
21. (Cancelled)
22. (Original) The method of claim 13, wherein said composition comprises taurultam.

Applicants: Calabresi et al.  
U.S.S.N. 10/796,861

23. (Original) The method of claim 13, wherein said composition comprises a taurultam derivative or metabolite.

24. (Original) The method of claim 13, further comprising administering a chemotherapeutic agent selected from the group consisting of an antimetabolite, a purine or pyrimidine analogue, an alkylating agent, an intercalating agent, a crosslinking agent, and an antibiotic.

25. - 77. (Cancelled)